Inhibrx Biosciences Inc (INBX) AI Stock Analysis

• Market Cap: $553.63M
• Dividend Yield: N/A
• Average Volume (3M): 142.18K
• Price to Earnings (P/E): 0.2
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -1.85
• Shares Outstanding: 14,485,421
• 10 Day Avg. Volume: 168,676
• 30 Day Avg. Volume: 142,179
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.67
• Price to Sales (P/S): 1114.64
• P/FCF Ratio: -1.13
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 100.68
• Enterprise Value/Gross Profit: -101.62
• Enterprise Value/Ebitda: -0.89
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: $79.00 ▲(0.62% Upside)

The overall stock score for Inhibrx Biosciences Inc is primarily influenced by its weak financial performance and valuation concerns, which are somewhat offset by strong technical indicators suggesting bullish momentum. However, the overbought technical signals and lack of profitability pose significant risks.

Positive Factors

Innovative Product Pipeline

The company's focus on innovative therapies for cancer and serious diseases positions it well in the biotechnology industry, which values breakthrough treatments. This pipeline can lead to significant long-term growth if clinical trials succeed.

Strategic Partnerships

Strategic collaborations with larger pharmaceutical companies provide essential funding and resources, enhancing the company's ability to advance its drug candidates through clinical trials and potentially to market.

External Financing Support

Securing external financing supports liquidity and provides the necessary capital to continue operations and fund research, which is crucial for a clinical-stage biotech firm with ongoing cash flow challenges.

Negative Factors

High Leverage

High leverage increases financial risk, especially if revenue does not improve. This reliance on debt can strain the company's financial health and limit its ability to invest in growth opportunities.

Negative Cash Flows

Consistently negative cash flows indicate operational inefficiencies and limit the company's ability to self-fund its development projects, increasing reliance on external funding and raising sustainability concerns.

Declining Revenues

Declining revenues highlight difficulties in achieving a sustainable growth trajectory, which is critical for long-term success, especially in the competitive biotech industry.

Inhibrx Biosciences Inc Business Overview & Revenue Model

Company Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

How the Company Makes Money

Inhibrx Biosciences generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, where it licenses its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These collaborations often provide the necessary funding for further development of its therapeutic candidates. Additionally, Inhibrx may receive grant funding or other financial support from governmental agencies or non-profit organizations aimed at advancing clinical research. As the company progresses its candidates through clinical trials and potentially toward commercialization, successful outcomes can lead to significant financial returns from both licensing agreements and eventual product sales.

Inhibrx Biosciences Inc Financial Statement Overview

Summary

Inhibrx Biosciences Inc faces significant operational challenges, with declining revenues and negative profitability margins. The balance sheet indicates high leverage with potential solvency risks, and cash flows are consistently negative, exacerbating financial concerns.

Income Statement

Inhibrx Biosciences Inc has faced significant challenges in revenue generation, with a decline from previous years and a negative EBIT and EBITDA margin indicating operational inefficiencies. Although there is a notable spike in net income for 2024, this appears to be an anomaly and not reflective of consistent profitability. Overall, the company struggles with achieving a sustainable revenue growth trajectory.

Balance Sheet

The company has shown some improvement in stockholders' equity, yet it remains heavily leveraged with a debt-to-equity ratio indicating high financial risk. The equity ratio is low, suggesting that the company relies significantly on debt financing, which could be risky if revenue does not improve. The high liabilities relative to assets further highlight potential solvency concerns.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing operational challenges. The free cash flow position is also negative, indicating limited internal generation of cash for reinvestment or debt repayment. However, the company has managed to secure external financing, which has supported liquidity but raises concerns about long-term financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.40M	200.00K	1.80M	2.19M	7.13M	12.81M
Gross Profit	-1.39M	-2.08M	609.00K	-107.99M	4.44M	-60.69M
EBITDA	-157.62M	1.70B	-206.69M	-125.82M	-75.37M	-66.42M
Net Income	-163.69M	1.69B	-241.36M	-145.23M	-81.77M	-75.64M
Balance Sheet
Total Assets	212.12M	180.77M	307.89M	290.88M	150.45M	143.74M
Cash, Cash Equivalents and Short-Term Investments	186.57M	152.60M	277.92M	273.87M	131.30M	128.66M
Total Debt	7.51M	8.05M	210.14M	207.10M	70.47M	37.45M
Total Liabilities	143.56M	47.18M	264.39M	232.82M	98.07M	68.27M
Stockholders Equity	68.56M	133.58M	43.50M	58.06M	52.38M	75.47M
Cash Flow
Free Cash Flow	-140.13M	-197.01M	-197.90M	-115.99M	-81.19M	-49.33M
Operating Cash Flow	-139.85M	-194.41M	-193.31M	-115.30M	-80.32M	-47.97M
Investing Cash Flow	-284.00K	-2.60M	-4.59M	-686.00K	-809.00K	-1.36M
Financing Cash Flow	102.55M	71.68M	201.96M	258.55M	83.77M	166.46M

Inhibrx Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 78.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 78.51 is above the 20-day moving average (MA) of 43.00, above the 50-day MA of 34.34, and above the 200-day MA of 20.01, indicating a bullish trend. The MACD of 10.01 indicates Negative momentum. The RSI at 84.34 is Negative, neither overbought nor oversold. The STOCH value of 96.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.

Inhibrx Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	―	$549.16M	5.82	108.21%	―	18.01%	306.76%
Sector *	―	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
INBX	―	$553.63M	0.20	-113.71%	―	―	―
PRTA	―	$564.14M	-1.86	-66.85%	―	-95.24%	-493.05%
GLUE	―	$771.99M	36.43	9.81%	―	2990.57%	―
HUMA	―	$303.38M	―	―	―	―	63.92%
CADL	―	$306.31M	―	-55.18%	―	―	60.29%

Inhibrx Biosciences Inc Corporate Events

Inhibrx’s Promising Study on INBRX-106 for Advanced Head and Neck Cancer

Inhibrx Biosciences, Inc. is conducting a pivotal clinical study titled ‘A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN).’ The study aims to evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with pembrolizumab compared to pembrolizumab alone in treating patients with advanced head and neck squamous cell carcinoma that cannot be cured by local therapies.

Inhibrx Biosciences Advances Cancer Treatment with INBRX-106 Study Update

Inhibrx Biosciences, Inc. is conducting a pivotal clinical study titled ‘An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and determine the maximum tolerated dose of INBRX-106, both as a standalone treatment and in combination with pembrolizumab, for patients with various advanced solid tumors. This research is significant as it explores new therapeutic options for conditions like non-small cell lung cancer, melanoma, and renal cell carcinoma.

Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment

Inhibrx Biosciences, Inc. is conducting a Phase 2 study titled ‘A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma.’ The study aims to evaluate the efficacy of INBRX-109, a tetravalent DR5 agonist antibody, in treating patients with unresectable or metastatic conventional chondrosarcoma. This research is significant as it explores a potential new treatment option for a challenging cancer type.

Inhibrx’s Phase 1 Study of INBRX-109: A Potential Game-Changer in Cancer Treatment

Inhibrx Biosciences, Inc. is conducting a Phase 1 study titled ‘An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas.’ The study aims to evaluate the safety and efficacy of INBRX-109, a tetravalent antibody targeting the death receptor 5 (DR5), in treating various advanced solid tumors, including sarcomas. This study is significant as it explores a novel therapeutic approach for challenging cancer types.

Inhibrx Biosciences Reports Positive ChonDRAgon Study Results

On October 23, 2025, Inhibrx Biosciences announced positive topline results from its ChonDRAgon study, showing that ozekibart significantly improved median progression-free survival in patients with advanced chondrosarcoma compared to placebo. This marks the first investigational therapy to demonstrate such benefits in this disease, which lacks approved systemic treatments. The company also reported promising interim data from expansion cohorts for colorectal cancer and Ewing sarcoma, indicating high response and disease control rates in heavily pretreated patients. Inhibrx plans to file a biologics license application with the FDA in the second quarter of 2026, potentially enhancing its positioning in the oncology market.

The most recent analyst rating on (INBX) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.

Inhibrx Biosciences Reports Q2 2025 Financial Results

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using advanced protein engineering techniques. The company operates within the biotechnology sector and is known for its innovative approaches to addressing complex disease biology.